YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy

• DOI: 10.3389/fonc.2021.607224
• Publication Date: 2021-05-06T06:26:07Z
• Authors: Jian Hu; Dongxu Qiu; Anze Yu; Jiao Hu; Hao Deng; Huihuang Li; Zhenglin Yi; Jinbo Chen; Xiongbing Zu
• Keywords: Cancer Immunotherapy

YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) has been indicated proven to participate in the cross-presentation of tumor antigens dendritic cells and cross-priming CD8+ T cells. However, role YTHDF1 prognosis immunology human cancers remains largely unknown.All original data were downloaded from TCGA GEO databases integrated via R 3.2.2. expression was explored with Oncomine, TIMER, GEPIA, BioGPS databases. The effect on analyzed Kaplan-Meier plotter, PrognoScan database. TISIDB database used determine different immune molecular subtypes cancers. correlations between checkpoints (ICP), mutational burden (TMB), microsatellite instability (MSI), neoantigens SangerBox relationships tumor-infiltrated TIMER GEPIA marker genes urogenital for confirmation. genomic alterations investigated c-BioPortal differential clinical characteristics UALCAN coexpression networks studied by LinkedOmics database.In general, higher tumors than paired normal tissue had strong prognosis, ICP, TMB, MSI, neoantigens. plays an essential microenvironment (TME) participates regulation. Furthermore, significant immune-infiltrated (TILs) existed cancers, TILs significantly related YTHDF TYHDF1 mostly participated regulation response antigen processing presentation.YTHDF1 may serve as a potential prognostic immunological pan-cancer biomarker. Moreover, could be novel target immunotherapy.